Angiotensin II Upregulates Endothelin Receptors Through the Adenosine Monophosphate-Activated Protein Kinase/sirtuin 1 Pathway in Vascular Smooth Muscle Cells.

Xin Zhang,Hongmei Zhang,Xinpu Yang,Qiaohong Qin,Xia Sun,Ying Hou,Di Chen,Min Jia,Xingli Su,Yulong Chen
DOI: https://doi.org/10.1093/jpp/rgab137
2021-01-01
Journal of Pharmacy and Pharmacology
Abstract:OBJECTIVES:This study was designed to test our hypothesis that angiotensin II (Ang II) upregulates endothelin (ET) receptors in vascular smooth muscle cells (VSMCs).METHODS:Rat superior mesenteric artery (SMA) without endothelium was cultured in serum-free medium for 24 h in the presence of Ang II with or without metformin or nicotinamide. In vivo, rats were implanted subcutaneously with a mini-osmotic pump infusing AngII (500 ng/kg/min) for 4 weeks. The level of protein expression was determined using Western blotting. The contractile response to ET receptor agonists was studied using sensitive myography. Caudal artery blood pressure (BP) was measured using non-invasive tail-cuff plethysmography.KEY FINDINGS:The results showed that Ang II significantly increased ET receptors and decreased phosphorylated-adenosine monophosphate-activated protein kinase α (p-AMPKα) in SMA. Furthermore, metformin significantly inhibited Ang II-upregulated ET receptors and upregulated Ang II-decreased sirtuin 1 (Sirt1). However, this effect was reversed by nicotinamide. Moreover, the in-vivo results showed that metformin not only inhibited Ang II-induced upregulation of ET receptors but also recovered Ang II-decreased p-AMPKα and Sirt1. In addition, metformin significantly inhibited Ang II-elevated BP. However, the effect was reversed by nicotinamide, except for p-AMPKα.CONCLUSIONS:Ang II upregulated ET receptors in VSMCs to elevate BP by inhibiting AMPK, thereby inhibiting Sirt1.
What problem does this paper attempt to address?